The fight against drug-resistant tuberculosis (TB) has taken a significant leap forward with recent findings from a clinical trial involving the oral antibiotic levofloxacin. Conducted by researchers at the University of Sydney’s Woolcock Institute of Medical Research in collaboration with the Vietnam Tuberculosis Program, the trial has demonstrated the efficacy and safety of levofloxacin in reducing the risk of developing multidrug-resistant TB (MDR-TB).
Published in the prestigious New England Journal of Medicine, the study reveals that taking levofloxacin once daily for six months can substantially lower the risk of progressing to MDR-TB. The trial’s results showed a reduction in the risk of developing the disease by nearly half among adults and children. Professor Gregory Fox, Director of the NHMRC Centre for Research Excellence in Tuberculosis, highlighted the global importance of these findings, especially given the annual impact of MDR-TB on over 400,000 individuals.
“Multidrug-resistant TB is a major global public health problem, associated with significantly poorer outcomes than drug-susceptible TB,” Professor Fox noted. “We now have a way of stopping people with early TB infection from becoming sick and spreading their infection to others.”
The trial, known as VQUIN, enrolled 2,041 family members of individuals with drug-resistant TB across 10 provinces in Vietnam, a region with a high incidence of the disease. These participants had early TB infections that had not yet progressed to active MDR-TB. The study’s design allowed researchers to monitor the effects of levofloxacin on preventing the advancement of the disease in these high-risk groups.
Findings from the VQUIN trial were bolstered by parallel results from the TB-CHAMP trial in South Africa, which focused on children receiving the same treatment. The combined analysis from both trials underscored the significant protective effect of levofloxacin in preventing MDR-TB in household contacts of infected individuals. Published concurrently in NEJM Evidence, the collective data provide a compelling argument for the adoption of levofloxacin as a preventive measure against MDR-TB.
Professor Fox emphasized the broader implications of these findings, stating, “This evidence changes the way we care for people at risk of drug-resistant TB in Australia and globally. The benefits to the families and communities at risk of MDR-TB are substantial.”
The trial’s outcomes are particularly encouraging for vulnerable populations, such as children, who have historically been overlooked in TB treatment protocols. Professor Ben Marais, another Chief Investigator from VQUIN and TB-CHAMP, underscored this point, noting the multiple dimensions of benefits that the preventive use of levofloxacin could offer. “By finding a way to protect vulnerable family members, we help the whole family recover from the effects of MDR-TB. There are not just health benefits, but also economic and mental health benefits,” he explained.
The trial demonstrated that participants who received levofloxacin experienced a 45 percent reduction in the incidence of TB compared to those who received a placebo. Despite a lower-than-expected number of TB cases in the placebo group, the protective effect of levofloxacin was clear. Importantly, the antibiotic was well-tolerated across all age groups, with minimal side effects reported.
TB remains one of the leading causes of death among children globally, particularly affecting those under five years old. With approximately 400,000 new cases of MDR-TB each year, the complexity and cost of treatment have posed significant challenges for both families and healthcare systems. The introduction of an effective preventive measure like levofloxacin could alleviate many of these burdens.
In response to these groundbreaking findings, the World Health Organization (WHO) updated its guidelines for MDR-TB preventive therapy in September 2024, incorporating the results from the VQUIN trial. The new guidelines recommend levofloxacin as a key component in preventing the progression of early TB infection to active MDR-TB.
Beyond the primary findings, the trial also explored various factors related to the treatment’s implementation, such as acceptability, feasibility, health economics, pharmacokinetics, and the potential for antimicrobial resistance. These comprehensive considerations ensure that the new treatment regimen can be effectively integrated into existing TB control programs worldwide.
The collaborative effort between the Australian and South African research teams exemplifies the importance of international partnerships in tackling global health issues. Before the trials were unblinded, the teams combined their data using traditional and Bayesian analytical approaches to reinforce the robustness of their conclusions. The Bayesian analysis, in particular, offered a novel perspective, confirming the consistency of the protective effect of levofloxacin across different populations and settings.
The VQUIN trial received funding from the Australian National Health and Medical Research Council (NHMRC) and was sponsored by the Woolcock Institute of Medical Research at the University of Sydney. Its successful implementation in partnership with the Vietnam National Tuberculosis Program highlights the critical role of collaborative research in addressing pressing public health challenges.
As the world continues to grapple with the threat of drug-resistant diseases, the findings from the VQUIN and TB-CHAMP trials provide a beacon of hope. Levofloxacin’s role in reducing the risk of MDR-TB marks a pivotal moment in the global fight against tuberculosis, promising a future where fewer families endure the devastating impact of this relentless disease.
Support independent community journalism. Support The Indian Sun.
Follow The Indian Sun on X | Instagram | Facebook
Support Independent Community Journalism
Dear Reader,The Indian Sun exists for one reason: to tell stories that might otherwise go unheard.
We report on local councils, state politics, small businesses and cultural festivals. We focus on the Indian diaspora and the wider multicultural community with care, balance and accountability. We publish in print and online, send regular newsletters and produce video content. We also run media training programs to help community organisations share their own stories.
We operate independently.
Community journalism does not have the backing of large media corporations. Advertising revenue fluctuates. Platform algorithms change. Costs continue to rise. Yet the need for credible, grounded reporting in a multicultural Australia has never been greater.
When you support The Indian Sun, you support:
• Independent reporting on issues affecting migrant communities
• Coverage of local and state decisions that shape daily life
• A platform for small businesses and community groups
• Media training that builds skills within the community
• Journalism accountable to readers
We cannot cover everything, but we work to cover what matters.
If you value thoughtful reporting that reflects Australia’s diversity, we invite you to contribute. Every donation helps us maintain the quality and consistency of our work.
Please consider making a contribution today.
Thank you for your support.
The Indian Sun Team
